

Equipe EMET « Evaluation et Modélisation des Effets des Thérapeutiques », EA3736

Articles en premier, second, troisième ou dernier auteur, par années

Référence	IF 2003
P1. <u>Boissel J.P.</u> , <u>Gueyffier F.</u> , and <u>Boutitie F.</u> (2002) Risk reduction for stroke and coronary events. <i>Lancet</i> 359:1249.	18,3
P2. <u>Bonnefoy E.</u> , Lapostolle F., <u>Leizorovicz A.</u> , Steg G., McFadden E.P., Dubien P.Y., Cattan S., Boullenger E., Machecourt J., Lacroute J.M., Cassagnes J., Dissait F., and Touboul P. (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. <i>Lancet</i> 360: 825-9.	18,3
P3. Boutitie F., <u>Gueyffier F.</u> , Pocock S.J., Fagard R., <u>Boissel J.P.</u> , on behalf of the INDANA Project Steering Committee (2002) Relationship between blood pressure and mortality in hypertensive patients randomised in non-active controlled clinical trials: a meta-analysis on individual patient data. <i>Ann. Intern. Med.</i> 136: 438-48.	12,4
P4. Hurot J.M., <u>Cucherat M.</u> , Haugh M., and Fouque D. (2002) Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. <i>J. Am. Soc. Nephrol.</i> 13: 708-14.	7,5
P5. Duval V., Chabaud S., Girard P., <u>Cucherat M.</u> , Hommel M., and <u>Boissel J.P.</u> (2002) Physiologically based model of acute ischemic stroke. <i>J. Cereb. Blood Flow Metab.</i> 22: 1010-8.	5,4
P6. Gasowski J., Fagard R.H., Staessen J.A., Grodzicki T., Pocock S., Boutitie F., <u>Gueyffier F.</u> , and <u>Boissel J.P.</u> (2002) Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. <i>J. Hypertens.</i> 20: 145-151.	3,6
P7. <u>Leizorovicz A.</u> , Lechat P., <u>Cucherat M.</u> , and Bugnard F. (2002) Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. <i>Cardiac Insufficiency Bisoprolol. Study. Am. Heart J.</i> 143: 301-307.	3,3
P8. <u>Lièvre M.</u> , <u>Cucherat M.</u> , and <u>Leizorovicz A.</u> (2002) Pooling, meta-analysis, and the evaluation of drug safety. <i>Cur. Cont. Trials Cardiovasc. Med.</i> 3: 6.	3,1
P9. Chabaud S., Girard P., <u>Nony P.</u> , <u>Boissel J.P.</u> on behalf of the THERMOS group (2002) Clinical trial simulation using therapeutic effect modelling: application to ivabradine efficacy in patients with angina pectoris. <i>J. Pharmacokinetics Pharmacodynamics</i> 29: 339-63.	1,6
P10. Etter J.F., <u>Cucherat M.</u> , and Perneger T.V. (2002) Questionnaire color and response rates to mailed surveys. A randomized trial and a meta-analysis. <i>Eval. Health Prof.</i> 25: 185-99.	1
P11. Strang N., <u>Cucherat M.</u> , and <u>Boissel J.P.</u> (2002) Which coding system for therapeutic information in evidence-based medicine. <i>Comput. Meth. Prog. Biomed.</i> 68: 73-85.	0,7

2003		
P12.	P.G., <u>Bonnefoy</u> E., Chabaud S., Lapostolle F., Dubien P.Y., Cristofini P., <u>Leizorovicz</u> A., and Touboul P. (2003) Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. <i>Circulation</i> 108: 2851-6.	11,2
P13.	Vaur L., Gueret P., <u>Lievre</u> M., Chabaud S., and Passa P. (2003) Development of Congestive Heart Failure in Type 2 Diabetic Patients With Microalbuminuria or Proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. <i>Diabetes Care</i> 26: 855-60.	7,5
P14.	<u>Gueyffier</u> F. (2003) Secondary Prevention of Stroke: Beyond Meta-Analyses. <i>Stroke</i> 34: 2748-9.	5,2
P15.	<u>Gueyffier</u> F. (2003) Observational epidemiological studies: values and limitations. <i>J. Hypertens.</i> 21: 673-5.	3,6
P16.	Becquemin J.P., Favre J.P., Marzelle J., Nemoz C., Corsin C., and <u>Leizorovicz</u> A. (2003) Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. <i>J. Vasc. Surg.</i> 37: 487-94.	3,5
P17.	Mahe I.I., <u>Leizorovicz</u> A., Caulin C., and Bergmann J.F. (2003) Aspirin for the Prevention of Cardiovascular Events in the Elderly. <i>Drugs Aging</i> 20: 999-1010.	2,8
P18.	Hulot J.S., <u>Cucherat</u> M., Charlesworth A., Van Veldhuisen D.J., Corvol J.C., Mallet A., <u>Boissel</u> J.P., Hampton J., and Lechat P. (2003) Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. <i>B. J. Clin. Pharmacol.</i> 55: 299-306.	2,5
P19.	<u>Kassai</u> B., <u>Gueyffier</u> F., <u>Boissel</u> J.P., Boutitie F., and <u>Cucherat</u> M. (2003) Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? <i>J. Clin. Epidemiol.</i> 56: 977-82.	2,2
P20.	<u>Boissel</u> J.P., <u>Gueyffier</u> F., <u>Cucherat</u> M., and Bricca G. (2003) Pharmacogenetics and responders to a therapy: theoretical background and practical problems. <i>Clin. Chem. Lab. Med.</i> 41: 564-72.	1,5
P21.	Darmoni S.J., Amsallem E., Haugh M., Lukacs B., Leroux V., Thirion B., Weber J., and <u>Boissel</u> J.P. (2003) Level of evidence as a future gold standard for the content quality of health resources on the internet. <i>Methods Inf. Med.</i> 42: 220-5.	1,4
P22.	<u>Boissel</u> J.P., Haugh M., Fardeheb M., <u>Nony</u> P., <u>Gueyffier</u> F., and Strang N. (2003) How should therapeutic information be transferred to users? <i>Fundam. Clin. Pharmacol.</i> 17: 495-503.	1
P23.	<u>Leizorovicz</u> A., <u>Kassai</u> B., Becker F., and <u>Cucherat</u> M. (2003) The assessment of deep vein thromboses for therapeutic trials. <i>Angiology</i> 54: 19-24.	0,9
P24.	<u>Boissel</u> J.P., <u>Cucherat</u> M., Amsallem E., <u>Nony</u> P., Fardeheb M., Manzi W., and Haugh M.C. (2003) Getting evidence to prescribers and patients or how to make EBM a reality Study. <i>Health Technol. Inform.</i> 95: 554-9.	?
P25.	<u>Cucherat</u> M., <u>Bonnefoy</u> E., and Tremeau G. (2003) Primary	?

angioplasty versus intravenous thrombolysis for acute myocardial infarction. <i>Cochrane Database Syst Rev.</i> 3:CD001560.	
2004	
P26. <u>Leizorovicz</u> A., and Mismetti P. (2004) Preventing venous thromboembolism in medical patients. <i>Circulation</i> 110: IV13-9.	11,2
P27. Uzzan B., Nicolas P., <u>Cucherat</u> M., and Perret G.Y. (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. <i>Cancer Res.</i> 64: 2941-55.	8,6
P28. Marre M., <u>Lievre</u> M., Chatellier G., Mann J.F., Passa P., and Menard J.; DIABHYCAR Study Investigators (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). <i>B.M.J.</i> 328: 495-18.	6,6
P29. Argaud L., Rioufol G., <u>Lièvre</u> M., Bontemps L., Legalery P., Stumpf M., Finet G., Itti R., André-Fouët X., and Ovize M. (2004) Preconditioning during coronary angioplasty: no influence of collateral perfusion or the size of the area at risk. <i>Eur. Heart J.</i> 25: 2019-25.	6,0
P30. <u>Kassai</u> B., <u>Boissel</u> J.P., <u>Cucherat</u> M., Sonie S., Shah N., and <u>Leizorovicz</u> A. (2004) A Systematic review of the accuracy of ultra sound in the diagnostic of deep venous thrombosis in asymptomatic patients. <i>Thromb. Haemost.</i> 91: 655-66.	4,9
P31. <u>Gueyffier</u> F. (2004) Are guidelines right to promote lifestyle interventions against hypertension? <i>J. Hypertens.</i> 22: 2055-6.	3,6
P32. <u>Boissel</u> J.P. (2004) Planning of clinical trials. <i>J. Intern. Med.</i> 255: 427-38.	3,3
P33. <u>Boissel</u> J.P., Amsallem E., <u>Cucherat</u> M., <u>Nony</u> P., and Haugh M.C. (2004) Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation. <i>Eur. J. Clin. Pharmacol.</i> 60: 609-16.	2,0
P34. Chevalier P., Burri H., Fahrat F., <u>Cucherat</u> M., Jegaden O., Obadia J.F., <u>Kirkorian</u> G., and Touboul P. (2004) Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation. <i>Eur. J. Cardiothorac. Surg.</i> 26: 330-5.	1,5
P35. Bossard N., <u>Boissel</u> F.H., and <u>Boissel</u> J.P. (2004) Level of evidence and therapeutic evaluation: need for more thoughts. <i>Fundam. Clin. Pharmacol.</i> 18: 365-72.	1
P36. Yzèbe D., and <u>Lièvre</u> M. (2004) Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials. <i>Fundam. Clin. Pharmacol.</i> 18: 581-92.	1
P37. Dronne M.A., <u>Boissel</u> J.P., Grenier E., Gilquin H., <u>Cucherat</u> M., Hommel M., Barbier E., and Bricca G. (2004) Mathematical modelling of an ischemic stroke: an integrative approach. <i>Acta Biotheor.</i> 5: 255-72.	0,6
P38. Cournot M., Cambou J.P., Ferrieres J., Grenier O., Herrmann M.A., Cantet C., and <u>Leizorovicz</u> A. (2004) [Management of the cardiology patient with polyvascular disease: PRISMA study] <i>Arch. Mal. Coeur Vaiss.</i> 97: 841-8.	?

P39.	<u>Leizorovicz</u> A., Turpie A.G., Cohen A.T., Dhillon K.S, Ai P., Wang C.J., for the SMART Study Group (2004) Epidemiology of Post-Operative Venous Thromboembolism in Asian Countries International. <i>Journal of Angiology</i> 13: 101–108.	-
P40.	<u>Leizorovicz</u> A., Cohen A., Turpie A., Olsson, C.G., Vaitkus P.T., and Goldhaber S.Z., for the PREVENT Medical Thromboprophylaxis Study Group (2004) A Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism. <i>Pharmacoepidemiology and drug safety</i> 11: 874-9.	-
P41.	<u>Lièvre</u> M., Vaur L., Genes N., and Marre M. (2004) Prescription of metformin and renal failure: are the present recommendations appropriate? <i>Pharmacoepidemiology and drug safety</i> 13 (suppl 1):S270.	-
P42.	Mismetti P., Laporte S., Zufferey P., Epinat M., Decousus H., and <u>Cucherat</u> M. (2004) Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. <i>J. Thromb. Haemost.</i> 2: 1058-70.	-
2005		
P43.	<u>Lièvre</u> M., and Abadie E. (2005) Discontinuation of Vioxx. <i>Lancet</i> 365: 23-24.	18,3
P44.	Machecourt J., <u>Bonnefoy</u> E., Vanzetto G., Motreff P., Marliere S., <u>Leizorovicz</u> A., Allenet B., Lacroute J.M., Cassagnes J., and Touboul P. (2005) Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study. <i>Journal of the American College of Cardiology</i> 45: 515-524.	7,6
P45.	Kucher N., <u>Leizorovicz</u> A., Vaitkus P.T, Cohen A.T., Turpie A.G., Olsson C.G., and Goldhaber S.Z. (2005) Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. <i>Arch. Intern. Med.</i> 165: 341-5.	6,7
P46.	Wang J.G., Staessen J.A., Franklin S.S., Fagard R., and <u>Gueyffier</u> F. (2005) Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. <i>Hypertension</i> 45: 907-13.	5,6
P47.	Vaitkus P.T., <u>Leizorovicz</u> A., Cohen A.T., Turpie A.G., Olsson C.G., Goldhaber S.Z.; and PREVENT Medical Thromboprophylaxis Study Group (2005) Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. <i>Thromb. Haemost.</i> 93: 76-9.	4,95
P48.	<u>Lièvre</u> M., Marre M., Robert J.J., Charpentier G., Iannascoli F., and Passa P., on behalf of the Diabetes, therapeutic Strategies and Complications (DISCO) investigators (2005) Cross-sectional study of care, socio-economic status and complications in young French patients with type 1 diabetes mellitus. <i>Diabetes Metab.</i> 31: 41-6.	1,1
P49.	<u>Bonnefoy</u> E., Godon P., <u>Kirkorian</u> G., Chabaud S., and Touboul P. (2005) Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. <i>Acta Cardiol.</i> 60: 165-70.	0,4
P50.	Amsallem E., Kasparian C., Haddour G., <u>Boissel</u> J.P., and <u>Nony</u> P. (2005) Phosphodiesterase III inhibitors for heart failure. <i>Cochrane</i>	?

<i>Database Syst. Rev.</i> 1: CD002230.	
P51. <u>Kassaï B.</u> , <u>Boissel J.P.</u> , <u>Cucherat M.</u> , Boutitie F., and <u>Gueyffier F.</u> (2005) Treatment of high blood pressure and gain in event-free life expectancy. <i>Vascular Health and Risk Management</i> 1: 163-169.	-
P52. Laporte S., <u>Cucherat M.</u> , and Mismetti P. (2005) Risk of bleeding with vitamin K antagonists compared with low-molecular-weight heparin after orthopedic surgery: a reply to a rebuttal. <i>J. Thromb. Haemost.</i> 3: 609-10.	-
P53. <u>Leizorovicz A.</u> , Turpie A.G., Cohen A.T., Wong L., Yoo M.C., Dans A., and SMART Study Group. (2005) Related Articles, Links Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. <i>J. Thromb. Haemost.</i> 3: 28-34.	-

Articles en premier, second, troisième ou dernier auteur, 2002-2005 confondues.

Référence	IF 2003
P54. <u>Boissel J.P.</u> , <u>Gueyffier F.</u> , and <u>Boutitie F.</u> (2002) Risk reduction for stroke and coronary events. <i>Lancet</i> 359:1249.	18,3
P55. <u>Bonnefoy E.</u> , Lapostolle F., <u>Leizorovicz A.</u> , Steg G., McFadden E.P., Dubien P.Y., Cattan S., Boullenger E., Machecourt J., Lacroute J.M., Cassagnes J., Dissait F., and Touboul P. (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. <i>Lancet</i> 360: 825-9.	18,3
P56. <u>Lièvre M.</u> , and Abadie E. (2005) Discontinuation of Vioxx. <i>Lancet</i> 365: 23-24.	18,3
P57. Boutitie F., <u>Gueyffier F.</u> , Pocock S.J., Fagard R., <u>Boissel J.P.</u> , on behalf of the INDANA Project Steering Committee (2002) Relationship between blood pressure and mortality in hypertensive patients randomised in non-active controlled clinical trials: a meta-analysis on individual patient data. <i>Ann. Intern. Med.</i> 136: 438-48.	12,4
P58. P.G., <u>Bonnefoy E.</u> , Chabaud S., Lapostolle F., Dubien P.Y., Cristofini P., <u>Leizorovicz A.</u> , and Touboul P. (2003) Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. <i>Circulation</i> 108: 2851-6.	11,2
P59. <u>Leizorovicz A.</u> , and Mismetti P. (2004) Preventing venous thromboembolism in medical patients. <i>Circulation</i> 110: IV13-9.	11,2
P60. Uzzan B., Nicolas P., <u>Cucherat M.</u> , and Perret G.Y. (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. <i>Cancer Res.</i> 64: 2941-55.	8,6
P61. Machecourt J., <u>Bonnefoy E.</u> , Vanzetto G., Motreff P., Marliere S., <u>Leizorovicz A.</u> , Allenet B., Lacroute J.M., Cassagnes J., and Touboul P. (2005) Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of	7,6

	Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study. <i>Journal of the American College of Cardiology</i> 45: 515-524 .	
P62.	Hurot J.M., <u>Cucherat</u> M., Haugh M., and Fouque D. (2002) Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. <i>J. Am. Soc. Nephrol.</i> 13: 708-14.	7,5
P63.	Vaur L., Gueret P., <u>Lievre</u> M., Chabaud S., and Passa P. (2003) Development of Congestive Heart Failure in Type 2 Diabetic Patients With Microalbuminuria or Proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. <i>Diabetes Care</i> 26: 855-60.	7,5
P64.	Kucher N., <u>Leizorovicz</u> A., Vaitkus P.T, Cohen A.T., Turpie A.G., Olsson C.G., and Goldhaber S.Z. (2005) Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. <i>Arch. Intern. Med.</i> 165: 341-5.	6,7
P65.	Marre M., <u>Lievre</u> M., Chatellier G., Mann J.F., Passa P., and Menard J.; DIABHYCAR Study Investigators (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). <i>B.M.J.</i> 328: 495 18.	6,6
P66.	Argaud L., Rioufol G., <u>Lièvre</u> M., Bontemps L., Legalery P., Stumpf M., Finet G., Itti R., André-Fouët X., and Ovize M. (2004) Preconditioning during coronary angioplasty: no influence of collateral perfusion or the size of the area at risk. <i>Eur. Heart J.</i> 25: 2019-25.	6,0
P67.	Wang J.G., Staessen J.A., Franklin S.S., Fagard R., and <u>Gueyffier</u> F. (2005) Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. <i>Hypertension</i> 45: 907-13.	5,6
P68.	Duval V., Chabaud S., Girard P., <u>Cucherat</u> M., Hommel M., and <u>Boissel</u> J.P. (2002) Physiologically based model of acute ischemic stroke. <i>J. Cereb. Blood Flow Metab.</i> 22: 1010-8.	5,4
P69.	<u>Gueyffier</u> F. (2003) Secondary Prevention of Stroke: Beyond Meta-Analyses. <i>Stroke</i> 34: 2748-9.	5,2
P70.	Vaitkus P.T., <u>Leizorovicz</u> A., Cohen A.T., Turpie A.G., Olsson C.G., Goldhaber S.Z.; and PREVENT Medical Thromboprophylaxis Study Group (2005) Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. <i>Thromb. Haemost.</i> 93: 76-9.	4,95
P71.	<u>Kassai</u> B., <u>Boissel</u> J.P., <u>Cucherat</u> M., Sonie S., Shah N., and <u>Leizorovicz</u> A. (2004) A Systematic review of the accuracy of ultra sound in the diagnostic of deep venous thrombosis in asymptomatic patients. <i>Thromb. Haemost.</i> 91: 655-66.	4,9
P72.	Gasowski J., Fagard R.H., Staessen J.A., Grodzicki T., Pocock S., Boutitie F., <u>Gueyffier</u> F., and <u>Boissel</u> J.P. (2002) Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. <i>J. Hypertens.</i> 20: 145-151.	3,6
P73.	<u>Gueyffier</u> F. (2003) Observational epidemiological studies: values and limitations. <i>J. Hypertens.</i> 21: 673-5.	3,6
P74.	<u>Gueyffier</u> F. (2004) Are guidelines right to promote lifestyle interventions against hypertension? <i>J. Hypertens.</i> 22: 2055-6.	3,6
P75.	Becquemin J.P., Favre J.P., Marzelle J., Nemoz C., Corsin C., and	3,5

	<u>Leizorovicz</u> A. (2003) Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. <i>J. Vasc. Surg.</i> 37: 487-94.	
P76.	<u>Leizorovicz</u> A., Lechat P., <u>Cucherat</u> M., and Bugnard F. (2002) Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. <i>Cardiac Insufficiency Bisoprolol. Study. Am. Heart J.</i> 143: 301-307.	3,3
P77.	<u>Boissel</u> J.P. (2004) Planning of clinical trials. <i>J. Intern. Med.</i> 255: 427-38.	3,3
P78.	<u>Lièvre</u> M., <u>Cucherat</u> M., and <u>Leizorovicz</u> A. (2002) Pooling, meta-analysis, and the evaluation of drug safety. <i>Cur. Cont. Trials Cardiovasc. Med.</i> 3: 6.	3,1
P79.	Mahe I.I., <u>Leizorovicz</u> A., Caulin C., and Bergmann J.F. (2003) Aspirin for the Prevention of Cardiovascular Events in the Elderly. <i>Drugs Aging</i> 20: 999-1010.	2,8
P80.	Hulot J.S., <u>Cucherat</u> M., Charlesworth A., Van Veldhuisen D.J., Corvol J.C., Mallet A., <u>Boissel</u> J.P., Hampton J., and Lechat P. (2003) Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. <i>B. J. Clin. Pharmacol.</i> 55: 299-306.	2,5
P81.	<u>Kassai</u> B., <u>Gueyffier</u> F., <u>Boissel</u> J.P., Boutitie F., and <u>Cucherat</u> M. (2003) Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? <i>J. Clin. Epidemiol.</i> 56: 977-82.	2,2
P82.	<u>Boissel</u> J.P., Amsallem E., <u>Cucherat</u> M., <u>Nony</u> P., and Haugh M.C. (2004) Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation. <i>Eur. J. Clin. Pharmacol.</i> 60: 609-16.	2,0
P83.	Chabaud S., Girard P., <u>Nony</u> P., <u>Boissel</u> J.P. on behalf of the THERMOS group (2002) Clinical trial simulation using therapeutic effect modelling: application to ivabradine efficacy in patients with angina pectoris. <i>J. Pharmacokinetics Pharmacodynamics</i> 29: 339-63.	1,6
P84.	<u>Boissel</u> J.P., <u>Gueyffier</u> F., <u>Cucherat</u> M., and Bricca G. (2003) Pharmacogenetics and responders to a therapy: theoretical background and practical problems. <i>Clin. Chem. Lab. Med.</i> 41: 564-72.	1,5
P85.	Chevalier P., Burri H., Fährat F., <u>Cucherat</u> M., Jegaden O., Obadia J.F., <u>Kirkorian</u> G., and Touboul P. (2004) Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation. <i>Eur. J. Cardiothorac. Surg.</i> 26: 330-5.	1,5
P86.	Darmoni S.J., Amsallem E., Haugh M., Lukacs B., Leroux V., Thirion B., Weber J., and <u>Boissel</u> J.P. (2003) Level of evidence as a future gold standard for the content quality of health resources on the internet. <i>Methods Inf. Med.</i> 42: 220-5.	1,4
P87.	<u>Lièvre</u> M., Marre M., Robert J.J., Charpentier G., Iannascoli F., and Passa P., on behalf of the Diabetes, therapeutic Strategies and Complications (DISCO) investigators (2005) Cross-sectional study of care, socio-economic status and complications in young French patients with type 1 diabetes mellitus. <i>Diabetes Metab.</i> 31: 41-6.	1,1
P88.	Etter J.F., <u>Cucherat</u> M., and Perneger T.V. (2002) Questionnaire color and response rates to mailed surveys. A randomized trial and a meta-analysis. <i>Eval. Health Prof.</i> 25: 185-99.	1

P89.	<u>Boissel</u> J.P., Haugh M., Fardeheb M., <u>Nony</u> P., <u>Gueyffier</u> F., and Strang N. (2003) How should therapeutic information be transferred to users? <i>Fundam. Clin. Pharmacol.</i> 17: 495-503.	1
P90.	Bossard N., <u>Boissel</u> F.H., and <u>Boissel</u> J.P. (2004) Level of evidence and therapeutic evaluation: need for more thoughts. <i>Fundam. Clin. Pharmacol.</i> 18: 365-72.	1
P91.	Yzèbe D., and <u>Lièvre</u> M. (2004) Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials. <i>Fundam. Clin. Pharmacol.</i> 18: 581-92.	1
P92.	<u>Leizorovicz</u> A., <u>Kassai</u> B., Becker F., and <u>Cucherat</u> M. (2003) The assessment of deep vein thromboses for therapeutic trials. <i>Angiology</i> 54: 19-24.	0,9
P93.	Strang N., <u>Cucherat</u> M., and <u>Boissel</u> J.P. (2002) Which coding system for therapeutic information in evidence-based medicine. <i>Comput. Meth. Prog. Biomed.</i> 68: 73-85.	0,7
P94.	Dronne M.A., <u>Boissel</u> J.P., Grenier E., Gilquin H., <u>Cucherat</u> M., Hommel M., Barbier E., and Bricca G. (2004) Mathematical modelling of an ischemic stroke: an integrative approach. <i>Acta Biotheor.</i> 5: 255-72.	0,6
P95.	<u>Bonnefooy</u> E., Godon P., <u>Kirkorian</u> G., Chabaud S., and Touboul P. (2005) Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. <i>Acta Cardiol.</i> 60: 165-70.	0,4
P96.	<u>Boissel</u> J.P., <u>Cucherat</u> M., Amsallem E., <u>Nony</u> P., Fardeheb M., Manzi W., and Haugh M.C. (2003) Getting evidence to prescribers and patients or how to make EBM a reality Study. <i>Health Technol. Inform.</i> 95: 554-9.	?
P97.	<u>Cucherat</u> M., <u>Bonnefooy</u> E., and Tremeau G. (2003) Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. <i>Cochrane Database Syst Rev.</i> 3:CD001560.	?
P98.	Cournot M., Cambou J.P., Ferrieres J., Grenier O., Herrmann M.A., Cantet C., and <u>Leizorovicz</u> A. (2004) [Management of the cardiology patient with polyvascular disease: PRISMA study] <i>Arch. Mal. Coeur Vaiss.</i> 97: 841-8.	?
P99.	<u>Leizorovicz</u> A., Turpie A.G., Cohen A.T., Dhillon K.S, Ai P., Wang C.J., for the SMART Study Group (2004) Epidemiology of Post-Operative Venous Thromboembolism in Asian Countries International. <i>Journal of Angiology</i> 13: 101–108.	-
P100.	<u>Leizorovicz</u> A., Cohen A., Turpie A., Olsson, C.G., Vaitkus P.T., and Goldhaber S.Z., for the PREVENT Medical Thromboprophylaxis Study Group (2004) A Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism. <i>Pharmacoepidemiology and drug safety</i> 11: 874-9.	-
P101.	<u>Lièvre</u> M., Vaur L., Genes N., and Marre M. (2004) Prescription of metformin and renal failure: are the present recommendations appropriate? <i>Pharmacoepidemiology and drug safety</i> 13 (suppl 1):S270.	-
P102.	Mismetti P., Laporte S., Zufferey P., Epinat M., Decousus H., and <u>Cucherat</u> M. (2004) Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. <i>J. Thromb. Haemost.</i> 2: 1058-70.	-

P103. Amsallem E., Kasparian C., Haddour G., <u>Boissel</u> J.P., and <u>Nony</u> P. (2005) Phosphodiesterase III inhibitors for heart failure. <i>Cochrane Database Syst. Rev.</i> 1: CD002230.	?
P104. <u>Kassaï</u> B., <u>Boissel</u> J.P., <u>Cucherat</u> M., Boutitie F., and <u>Gueyffier</u> F. (2005) Treatment of high blood pressure and gain in event-free life expectancy. <i>Vascular Health and Risk Management</i> 1: 163-169.	-
P105. Laporte S., <u>Cucherat</u> M., and Mismetti P. (2005) Risk of bleeding with vitamin K antagonists compared with low-molecular-weight heparin after orthopedic surgery: a reply to a rebuttal. <i>J. Thromb. Haemost.</i> 3: 609-10.	-
P106. <u>Leizorovicz</u> A., Turpie A.G., Cohen A.T., Wong L., Yoo M.C., Dans A., and SMART Study Group. (2005) Related Articles, Links Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. <i>J. Thromb. Haemost.</i> 3: 28-34.	-

Gilbert Kirkorian

	Impact factor
Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. (2003). Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. <i>J Am Coll Cardiol</i> 41;255-262	7,6
Chevalier P., Burri H., Fahrat F., Cucherat M., Jegaden O., Obadia J.F., Kirkorian G., and Touboul P. (2004) Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation. <i>Eur. J. Cardiothorac. Surg.</i> 26: 330-5.	1,5
Kirkorian G. (2005) Cardiac-resynchronization therapy in heart failure. <i>N Engl J Med</i> 353:205-206	31

Eric Bonnefoy

	Impact factor
Bonnefoy E., Lapostolle F., Leizorovicz A., Steg G., McFadden E.P., Dubien P.Y., Cattan S., Boullenger E., Machecourt J., Lacroute J.M., Cassagnes J., Dissait F., and Touboul P. (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. <i>Lancet</i> 360: 825-9.	18,3
Steg P.G., Bonnefoy E., Chabaud S., Lapostolle F., Dubien P.Y., Cristofini P., Leizorovicz A., and Touboul P. (2003) Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized	11,2

clinical trial. <i>Circulation</i> 108: 2851-6.	
Machecourt J., Bonnefoy E., Vanzetto G., Motreff P., Marliere S., Leizorovicz A., Allenet B., Lacroute J.M., Cassagnes J., and Touboul P. (2005) Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study. <i>Journal of the American College of Cardiology</i> 45: 515-524 .	7,6

Laurent François

	Impact factor
Steg PG, Francois L, Iung B, Himbert D, Aubry P, Charlier P, Benamer H, Feldman LJ, Juliard JMB. (2005) Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. <i>Eur Heart J.</i> 26:1831-1837	6,0

Financements

L'étude CAPTIM a fait l'objet d'un financement par PHRC. Elle a impliqué des centres hospitaliers au niveau national. Des projets sont en cours avec le Centre Hospitalier Universitaire de Genève

Comités de lecture

Gilbert Kirkorian est régulièrement sollicité pour reviewer du Journal of the American College of Cardiology

Eric Bonnefoy est sollicité comme reviewer par l'European Heart Journal, Heart et le Lancet.